Christopher Simon is President and Chief Executive Officer of Haemonetics Corp (HAE). The company reported total compensation of $12,044,701 for fiscal year 2026.
| Salary | $1,100,008 |
|---|---|
| Bonus | $0 |
| Stock awards | $7,561,987 |
| Option awards | $1,504,968 |
| Non-equity incentive plan | $1,834,250 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $43,488 |
| Total | $12,044,701 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Haemonetics Corp filed June 9, 2026, accession 0000313143-26-000074.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2026 | President and Chief Executive Officer | $1,100,008 | $0 | $7,561,987 | $1,504,968 | $1,834,250 | $0 | $43,488 | $12,044,701 |
| FY2025 | President and Chief Executive Officer | $1,100,000 | $0 | $7,026,668 | $1,399,974 | $1,131,625 | $0 | $64,221 | $10,722,488 |
| FY2024 | President and Chief Executive Officer | $1,088,469 | $0 | $6,320,923 | $1,624,959 | $2,447,500 | $0 | $63,262 | $11,545,113 |
| FY2023 | President and Chief Executive Officer | $1,012,885 | $0 | $5,924,933 | $1,499,980 | $2,200,000 | $0 | $48,597 | $10,686,395 |
Totals as disclosed in each year's own compensation disclosure for Haemonetics Corp.
| Peer-group chief executive median | $8,763,366 |
|---|---|
| Difference from that median | $3,281,335 |
| Percentile within the disclosed peer group | 75th |
| Peers with a disclosed figure | 15 |
Medians and percentiles are computed across the peer group Haemonetics Corp discloses in its own compensation disclosure.
| Named executive officer | Role | FY2026 total |
|---|---|---|
| Christopher Simon this page | President and Chief Executive Officer | $12,044,701 |
| James D'Arecca | Executive Vice President, Chief Financial Officer | $3,623,016 |
| Michelle Basil | Executive Vice President, General Counsel | $3,409,543 |
| Frank Chan | Executive Vice President, Chief Operating Officer | $3,336,849 |
| Roy Galvin | Executive Vice President, Chief Commercial Officer | $3,039,118 |
The company's named executive officers for fiscal year 2026, and what it reported for each. See the full Haemonetics Corp compensation brief.
Christopher Simon's compensation sits inside Haemonetics Corp's full executive and board picture — the peer group, pay against peers, incentive design and the board itself.